Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
$15.67
-$0.66(-5.31%)
At close: 4:00 PM EST
$15.67
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)211.48K
Market Cap
$521.93M
Enterprise Value$572.47M
Total Cash (Recent Filing)$60.01M
Total Debt (Recent Filing)$71.18M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Mar 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding33,307,735
10 Day Avg. Volume167,142
30 Day Avg. Volume211,483
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)40.67
Price to Sales (P/S)4.08
P/FCF Ratio-17.85
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.03
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda-37.76
Forecast
1Y Price Target
$20.00Price Target Upside27.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst OutlookAnalyst upgrade to valuation multiple and price target based on potential label expansion signals increased investor confidence in future commercial upside.
Commercial StrategyStrategic shift toward higher‑margin, personalized neuromodulation products is positioned to improve profitability by raising gross margins and concentrating resources on premium offerings.
Market OpportunityA meaningful share of patients with idiopathic generalized epilepsy are resistant to antiseizure medications and lack approved neuromodulation or surgical options, creating a clear addressable market for the RNS system.
Bears Say
Clinical Trial RiskA pivotal study failed to meet its primary effectiveness endpoint, creating uncertainty around regulatory approval prospects and clinician confidence in the indication.
Data Consistency ConcernsMissed primary endpoints at intermediate assessments, despite some later improvements on secondary measures, introduce inconsistency that could complicate regulatory review and adoption by physicians.
Distribution And Revenue RiskDecision not to renew the distribution agreement with a commercial partner reduces near‑term revenue visibility and may disrupt established sales channels, pressuring short‑term financial performance.
NeuroPace News
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $521.93M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is Mar 10, 2026 which is in 29 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.085.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.15.
How many shares outstanding does NeuroPace have?
NeuroPace has 33,307,735 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 38.085%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (27.63% Upside)
$20.00 (27.63% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 578.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 40.3%
Last 30 Days ▲ 40.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.71%
12-Months-Change
Fundamentals
Return on Equity
-169.27%
Trailing 12-Months
Asset Growth
11.37%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, positive adjusted EBITDA, and increased guidance. There were challenges, including the winding down of the DIXI product line and extended timelines for pediatric indication, but these were outweighed by positive developments and strategic progress.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$20.00
▲(27.63% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---